iRhythm Builds Momentum Following Large Trial Of AI Approach To ECG Analysis

 
• By Reed Miller
  
Generate a summary of this article
Listen to this article
Beta

Results from a study of more than 91,000 ECG records collected with iRhythm’s Zio ambulatory continuous cardiac monitoring device that demonstrates the successful application of artificial intelligence to ECGs gives the 12-year-old company confidence that it will be profitable very soon.

Zio XT Patch Side View
iRhythm's Zio XT ECG Monitor • Source: iRhythm Technologies, Inc.

Electrocardiography (ECG) data collected by iRhythm Technologies Inc.'s Zio ambulatory continuous-care wearable ECG monitor can be analyzed by a “deep learning” artificial intelligence model to detect cardiac arrhythmias as effectively as a panel of expert cardiologists across 12 kinds of cardiac rhythm outputs, according to the results of a 53,549-patient trial.

“Diagnosing arrhythmia is like a needle in a haystack problem,” iRhythm Executive VP-Research & Development Mark Day told Medtech Insight....

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

SpotifyApple PodcastsWebsite

More from Clinical Trials

Digital Health Roundup: Digital Therapeutics Navigate GLP-1, Immersive Gaming; DHCoE AI Framework; Hello Heart

In this week’s Digital Health Roundup, Medtech Insight’s Ryan Nelson highlights Click Therapeutics’ FDA-cleared digital therapeutics (DTx) for depression and Sinaptica Therapeutics’ personalized neuromodulation for Alzheimer’s patients. Marion Webb discusses her interview with MindMaze’s John Krakauer on their gaming-focused DTx to help people recover from serious brain injuries. Elizabeth Orr introduces new voting members of the new Digital Health Advisory Committee and Natasha Barrow discusses Hello Heart’s new symptom-tracking feature in their heart-focused app.

MI-Business (Free-2): Prison Is the First Mental Health Visit for Many in Spain

 
• By Nabil

Spain has one of the highest incarceration rates in Europe, with 160 individuals imprisoned per 100,000 residents. In 2020, 43,494 people were incarcerated in facilities not managed by regional health authorities — essentially all regions except Catalonia, the Basque Country, and Navarra.

TRiCares Initiates EU Pivotal Study For Topaz Tricuspid Valve Replacement

 
• By Natasha Barrow

TRiCares announced first implantation of the Topaz transfemoral tricuspid heart valve replacement system as part of the company’s EU pivotal study. If all goes to plan, the device will compete with Edwards’ Evoque system. The announcement follows the company’s $50m series D funding raise in July.

J&J MedTech Keeps Up Cardiovascular Momentum With Shockwave E8 Launch In US

Tim Schmid, executive VP and worldwide chairman of J&J MedTech, expects Shockwave, acquired in April, and Abiomed, purchased in late 2022, to be “long-term gems” for the company. Cardiovascular is among higher-growth segments where J&J has concentrated investments in recent years, along with robotic surgical systems.

More from R&D

Owkin Teams With AstraZeneca To Develop AI-Based Breast Cancer Prescreening Tool

 
• By Natasha Barrow

Biopharmaceutical giant AstraZeneca has partnered with start-up “unicorn” Owkin to develop an AI-powered tool to prescreen for gBRCA mutations on the basis of morphological features in digitized pathology slides. Built on extensive, high-quality data sourced from the France-based PortrAIt consortium, the AI will help to prioritize patients for further testing, streamlining the diagnostic process, Owkin says.

Route 92 To Drive FreeClimb Neurointervention Sales With Extended Series F Funding

 
• By Natasha Barrow

An additional $50m brings the neurovascular intervention specialist’s total Series F funding to $82m. Route 92 says it will use the capital to build its sales and support teams and pursue regulatory authorizations around the globe for its FreeClimb portfolio while advancing its SUMMIT MAX clinical trial for the investigational Monopoint Reperfusion System.

TRiCares Initiates EU Pivotal Study For Topaz Tricuspid Valve Replacement

 
• By Natasha Barrow

TRiCares announced first implantation of the Topaz transfemoral tricuspid heart valve replacement system as part of the company’s EU pivotal study. If all goes to plan, the device will compete with Edwards’ Evoque system. The announcement follows the company’s $50m series D funding raise in July.